KR20240086743A - Novel Leuconostoc mesenteroides VITA-PB2, KCTC19046P and composition for relieving hangover comprising thereof - Google Patents

Abstract

The novel lactic acid bacterium Leuconostoc mesenteroides VITA-PB2 (KCTC19046P) of the present invention has significantly high alcohol dehydrogenase and acetaldehyde dehydrogenase activities, preventing alcoholic liver disease caused by acetaldehyde. And because it has excellent hangover relieving activity, it can be used as a dairy product, health functional food, or food additive for this purpose.

Description

Novel lactic acid bacterium Leuconostoc mesenteroides VITA-PB2 (KCTC19046P) and hangover relief composition comprising the same {Novel Leuconostoc mesenteroides VITA-PB2, KCTC19046P and composition for relieving hangover comprising the same}

The present invention is a novel lactic acid bacterium Leuconostoc mesenteroides VITA-PB2 ( Leuconostoc mesenteroides VITA-PB2, KCTC19046P) and a hangover relief composition containing it.

Alcohol consumption is increasing every year, and the incidence of alcohol-related diseases is also increasing accordingly. The representative cause of alcoholic liver disease is acetaldehyde, which is produced when alcohol is broken down by enzymes, which damages liver cells. Alcoholic liver disease is largely classified into alcoholic fatty liver disease, alcoholic hepatitis, and alcoholic liver cirrhosis, and the damage mechanisms include alcohol itself, acetaldehyde, and immune response.

When alcohol is consumed, approximately 20% is absorbed from the stomach and most of the remainder is absorbed from the small intestine. Of these, 80-90% of absorbed alcohol is broken down by enzymes in the liver, and a small amount is broken down by intestinal microorganisms in the large intestine. At this time, alcohol is decomposed quickly, but it takes a relatively long time to decompose acetaldehyde. Undecomposed acetaldehyde stays in the intestines and directly damages the intestinal wall and is partially absorbed, causing various symptoms, the representative symptom on the surface being ‘hangover’. Therefore, if the small and large intestines can process larger amounts of alcohol and acetaldehyde, it can reduce hangovers and the burden on the liver, and further reduce liver damage and liver disease.

Recently, the human microbiome has been attracting attention as interest in intestinal microorganisms has increased rapidly for the purpose of relieving hangovers and preventing liver disease. Microbiome, or flora, is a general term for ‘various microorganisms such as bacteria and viruses at the individual level living in the human body.’ It is known that a 70kg adult has approximately 38 trillion microorganisms. It has been reported that as a person grows from birth, the microbiome changes in various ways, affecting human disease and health. At this time, the formation of a healthy intestinal microbiome has beneficial effects such as helping to facilitate digestion or preventing disease by preventing disease-causing bacteria from sticking to the intestinal wall.

As the importance of a healthy intestinal microbiome balance is emphasized, lactic acid bacteria not only serve as beneficial bacteria to prevent the invasion of harmful bacteria, but also provide various functions such as aiding digestion, suppressing fat accumulation, and decomposing ethanol and acetaldehyde. It is reported that it has the potential to be used in various fields, and research is actively underway for its use in various fields.

Some of the lactic acid bacteria known as beneficial intestinal bacteria can help metabolize alcohol in the small intestine by producing alcohol dehydrogenase (ADH) and acetaldehyde dehydrogenase (ALDH), and coenzymes that can increase the activity of ADH and ALDH. It is known to produce .

In particular, lactic acid bacteria are mainly isolated from fermented foods and are a material with excellent safety, so if you use lactic acid bacteria material that decomposes alcohol and acetaldehyde, it quickly decomposes not only alcohol but also acetaldehyde, the cause of hangovers, and has the effect of fundamentally relieving hangovers and improving liver health. Not only can we expect the effect of reducing the burden, but furthermore, by settling in the intestines, we can expect a safe and sustainable effect rather than a one-off effect.

Korean Patent Publication No. 10-2020-0062654, composition for relieving hangover containing fermented lactic acid bacteria. June 4, 2020. open. Korean Patent No. 10-1014867, fermented soybean product fermented with kimchi lactic acid bacteria, ramen for relieving hangover containing the fermented soybean product, herbal medicine composition, and five grain powder, and method for manufacturing them, February 8, 2011 Day. registration. Korean Patent No. 10-2046357, Hangover relief drink using fermented yellow chili extract and manufacturing method thereof, November 13, 2019. registration.

The purpose of the present invention is to provide lactic acid bacteria with high alcohol and acetaldehyde decomposition activity and excellent hangover relieving activity and preventing alcoholic liver disease caused by acetaldehyde. The object of the present invention is to develop a novel lactic acid bacterium Leuconostoc mesenteroides VITA-PB2 ( Leuconostoc mesenteroides VITA-PB2, KCTC19046P) and a hangover relief composition containing it.

The present invention relates to Leuconostoc mesenteroides VITA-PB2 ( Leuconostoc mesenteroid es VITA-PB2, KCTC19046P). The strain is a new strain of Leuconostoc mesenteroides with the 16S rRNA gene base sequence as shown in Figure 1 .

The present invention provides a composition for relieving hangovers containing the new strain Leuconostoc mesenteroides VITA-PB2 (KCTC19046P) or its culture solution.

The pharmaceutical composition can have a hangover relieving effect through its excellent acetaldehyde decomposition ability.

The new strain Leuconostoc mesenteroides VITA-PB2 (KCTC19046P) or its culture medium is preferably 0.001 to 99% by weight, more preferably 0.001 to 60% by weight, based on the total weight of the entire pharmaceutical composition. %, most preferably 0.001 to 40% by weight.

The pharmaceutical composition may be formulated and used in dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, liquids, aerosols, etc. according to conventional methods, but is not limited thereto. Carriers, excipients, and diluents that may be included in the pharmaceutical composition include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, and cellulose. , methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. When formulated, it can be prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, surfactants, sweeteners, and acidulants. Solid preparations for oral administration may be prepared by mixing one or more excipients, such as starch, calcium carbonate, sucrose or lactose, and gelatin. Liquid preparations for oral use may include suspensions, oral solutions, emulsions, and syrups. In addition to simple diluents such as water and liquid paraffin, various excipients such as wetting agents, sweeteners, fragrances, preservatives, and acidulants are included. may be included.

The dosage of the pharmaceutical composition of the present invention will vary depending on the age, gender, and weight of the subject to be treated, the specific disease or pathological state to be treated, the severity of the disease or pathological state, the route of administration, and the judgment of the prescriber. Dosage determinations based on these factors are within the level of one skilled in the art, and dosages generally range from 0.01 mg/kg/day to approximately 500 mg/kg/day. A preferred dosage is 0.1 mg/kg/day to 200 mg/kg/day, and a more preferred dosage is 1 mg/kg/day to 200 mg/kg/day. Administration may be administered once a day, or may be administered several times. The above dosage does not limit the scope of the present invention in any way.

The pharmaceutical composition of the present invention can be administered to mammals such as rats, livestock, and humans through various routes. The pharmaceutical composition of the present invention has almost no toxicity and side effects, so it can be safely used even when taken for a long period of time for preventive purposes.

The present invention provides a food for relieving hangovers containing the new strain Leuconostoc mesenteroides VITA-PB2 (KCTC19046P) or its culture solution. The food may be any one of fermented milk, fermented red ginseng food, fermented soybean food, cheese, dairy products, soy milk, tofu, beverage, powdered milk, baby food, raw food, beverage, sun food, or health supplement, but is not limited thereto. The food may contain food auxiliary additives that are foodologically acceptable.

The food contains Leuconostoc mesenteroides VITA-PB2 (KCTC19046P) or its culture solution in an amount of preferably 0.001 to 99% by weight, more preferably 0.001 to 60% by weight, based on the total weight of the entire food. , most preferably 0.001 to 40% by weight.

The food includes tablets, capsules, pills, or liquid forms. Foods to which the extract of the present invention can be added include, for example, various foods, beverages, gum, tea, vitamin complexes, and health functional foods. It may be, etc.

The novel lactic acid bacterium Leuconostoc mesenteroides VITA-PB2 (KCTC19046P) of the present invention has significantly high alcohol dehydrogenase and acetaldehyde dehydrogenase activities, preventing alcoholic liver disease and relieving hangovers. Because it has excellent activity, it can be used as a dairy product, health functional food, or food additive.

Figure 1 shows the base sequence of the 16S rRNA gene of Leuconostoc mesenteroides VITA-PB2 (KCTC19046P) of the present invention.
Figure 2 is a graph showing the alcohol dehydrogenase (ADH) activity results of Leuconostoc mesenteroides VITA-PB2 (KCTC19046P) of the present invention.
Figure 3 is a graph showing the results of aldehyde dehydrogenase (ALDH) activity of Leuconostoc mesenteroides VITA-PB2 (KCTC19046P) of the present invention.
Figure 4 is a photograph showing the results of a hemolysis stability test of Leuconostoc mesenteroides VITA-PB2 (KCTC19046P) of the present invention.
Figure 5 is a graph showing the results of a cytotoxicity test of Leuconostoc mesenteroides VITA-PB2 (KCTC19046P) of the present invention.
Figure 6 is a result showing the bile salt deconjugation stability results of Leuconostoc mesenteroides VITA-PB2 (KCTC19046P) of the present invention.

Hereinafter, preferred embodiments of the present invention will be described in detail. However, the present invention is not limited to the embodiments described herein and may be embodied in other forms, and the content introduced here is provided to sufficiently convey the spirit of the present invention.

< Example 1. Isolation of lactic acid bacteria>

Lactic acid bacteria were isolated from kimchi obtained from Cheongju, Daejeon, and Hwaseong, Gyeonggi-do. To isolate lactic acid bacteria, each sample was suspended in 0.85% physiological saline, and the suspension was spread on MRS agar medium containing vancomycin and cultured at 37°C for 24 hours. After culturing, colonies formed on MRS agar with different morphology were selected, passaged into MRS broth medium, and cultured at 37°C for 24 hours. Among the isolated strains, 205 strains with a culture medium pH of 5.0 or less were selected, and the selected strains were confirmed to produce lactic acid through BCP agar medium.

< Example 2. Alcohol tolerance and Acetaldehyde Selection of lactic acid bacteria with degrading ability>

2.1 Culture of lactic acid bacteria

The lactic acid bacteria isolated in Example 1 were pre-cultured in MRS broth medium at 37°C for 6 hours, then inoculated into MRS brtoh medium at a concentration of 2% and subcultured at 37°C for 16 hours. The cultured bacteria were centrifuged at 10°C and 6,000 rpm for 5 minutes to recover the cells, and washed three times using phosphate buffer (PBS buffer, pH 7.4). The finally obtained bacterial suspension was used in the experiment.

2.2 Selection of alcohol-resistant lactic acid bacteria

A 10% alcohol tolerance test was performed on the 205 strains isolated in Example 1. Strains with alcohol tolerance have ADH or ALDH activity, meaning that they can be decomposed in an environment where alcohol is present and used as a carbon source. Therefore, a strain with alcohol tolerance may be a strain with a high ability to decompose alcohol and acetaldehyde.

A reaction solution was prepared by adding ethanol to the MRS broth medium to a final concentration of 10%, and 1 ml of this solution was dispensed into 1.5 ml Eppendorf tubes. Thereafter, the suspension of 205 strains selected in Example 1 and cultured according to the method in Example 2.1 was reacted in a reaction solution containing ethanol at a ratio of 1:9 and cultured at 37°C for 6 hours. The optical density (O.D) of the strain suspension was compared at a wavelength of 600 nm at 2-hour reaction time intervals. By comparing the O.D. values before and after the reaction, strains whose absorbance value increased by about 20% or more were judged to be resistant to alcohol at a concentration of 10%, and 92 alcohol-resistant strains were selected using the above method.

2.3 Acetaldehyde Selection of lactic acid bacteria with degrading ability

To determine whether the 92 strains selected in Example 2.2 effectively decompose acetaldehyde, the causative agent of hangovers, the acetaldehyde decomposition ability of each strain was analyzed. A bacterial suspension of 92 strains was prepared in the same manner as in Example 2.1, and a reaction solution was prepared by adding acetaldehyde to MRS broth medium to a concentration of 200 μg/ml. The strain suspension was inoculated at a ratio of 1:15 with the prepared reaction solution, and reacted at 37°C for 4 hours using a shaking incubator. Afterwards, the reaction solution was recovered and centrifuged for 3 minutes at 10°C and 13,000 rpm, and the remaining acetaldehyde in each lactic acid bacteria culture supernatant was analyzed using the Megazyme acetaldehyde assay kit (Megazyme). The decomposition degree of 7 strains is shown in Table 1. As a control, a sample in which tertiary distilled water was added to the reaction solution at a ratio of 1:15 was used.

number sample name Acetaldehyde decomposition degree (%) - Control group (MRS broth) - One VITA-C8 85.4 2 VITA-R1W4 58.7 3 VITA-R1W5 64.5 4 VITA-R2W3 60.7 5 VITA-PB2 99.6 6 VITA-PB8 99.1 7 VITA-PY1 97.0

As shown in Table 1, 7 of the 92 selected alcohol-resistant strains showed acetaldehyde decomposition ability of more than 50%. Among these, three strains, VITA-PB2, VITA-PB8, and VITA-PY1, which showed excellent acetaldehyde decomposition ability of over 95%, were selected.

2.4 Identification of selected strains

The identification results of two positive control strains isolated from commercially available hangover relief products, including the three strains with alcohol tolerance and acetaldehyde decomposition ability selected above, are shown in Table 2. As a result of identification, all three strains selected in Example 2.3 were Leuconostoc mesenteroids ( Leuconostoc mesenteroides ).

number sample name fungal species One Positive control 1 (PC1) Lactobacillus brevis 2 Positive control 2 (PC2) Lactobacillus fermentum 3 KCTC 3505 Leuconostoc mesenteroides 4 KCTC 3528 Leuconostoc lactis 5 VITA-PB2 Leuconostoc mesenteroides 6 VITA-PB8 Leuconostoc mesenteroides 7 VITA-PY1 Leuconostoc mesenteroides

< Example 3. Leuconostoc mesenteroid Confirmation of alcohol metabolic activity of VITA-PB2>

3.1 Strains of crude extract manufacturing

In Table 2 above Seven types of strains were cultured in the same manner as Example 2.1 to prepare a bacterial suspension. The suspension of the seven strains was adjusted using 0.85% physiological saline so that the optical density (OD) was 1.0. Next, disruption was performed for 5 minutes using an ultrasonic cell disruptor (Ultrasonic Processor VCX-130, Sonics). The cell homogenate after complete disruption was centrifuged for 30 minutes at 4°C and 13,000 rpm, and the crude extract of the strain finally obtained was stored at -75°C and used in experiments. The protein content of the crude extract of each strain was analyzed using the Bradford assay. Afterwards, alcohol degrading enzyme (ADH) and acetaldehyde degrading enzyme (ALDH) activities were measured using spectrophotometry to measure the degree of NADH reduction in the crude extract of each strain, and calculated based on protein (mg protein) and the amount of NADH produced per hour. .

3.2 Alcohol dehydrogenase of the strain (Alcohol dehydrogenase , ADH ) activity measurement

In Table 2 above The alcohol-degrading enzyme activity of seven strains was measured. First, a reaction solution was prepared so that the final concentration was 2.5mM NAD and 25mM ethanol in 0.1M Glycine buffer (pH 9.6). The crude extract of each strain prepared in Example 3.1 and the reaction solution were reacted at 25°C for 5 minutes at a ratio of 1:9. After the reaction was completed, the amount of NADH produced was measured at 340 nm using a spectrophotometer, and the results are shown in Figure 2.

As shown in Figure 2, as a result of alcohol dehydrogenase activity analysis of the 7 strains including the 3 strains selected above, VITA-PB2, VITA-PB8, and VITA-PY1, the VITA-PB2 strain showed the highest alcohol dehydrogenase activity. It was. In particular, the VITA-PB2 strain of the present invention has an alcohol dehydrogenase activity of 1714.9 nmol NADH/min/mg protein compared to the same species standard strain, Leuconostoc mesenteroides KCTC 3505 (508.3 nmol NADH/min/mg protein). It was confirmed to be more than 3 times higher, and compared to the positive controls P.C1 ( Lactobacillus brevis ) or P.C2 ( Lactobacillus fermentum ), it shows about 2 to 3 times higher alcohol dehydrogenase activity and has an excellent alcohol decomposition ability. was confirmed.

3.3 Strains of Acetaldehyde Dehydrogenase (Acetaldehyde) dehydrogenase , ALDH ) activity measurement

In Table 2 above Acetaldehyde-decomposing enzyme activity of seven strains was measured. First, the final concentration of 1mM NAD was added to 60mM sodium pyrophosphate buffer (pH 8.8). A reaction solution was prepared by adding 0.2mM acetaldehyde and 0.1mM 4-methylpyrazole. The crude extract of each strain prepared above was reacted with the reaction solution at a ratio of 1:9 for 5 minutes at 25°C. After the reaction was completed, the amount of NADH produced was measured at 340 nm using a spectrophotometer, and the results are shown in Figure 3.

As shown in Figure 3, as a result of analyzing the acetaldehyde dehydrogenase activity of the 7 strains including the 3 strains selected above, VITA-PB2, VITA-PB8, and VITA-PY1, the VITA-PB2 strain had the highest acetaldehyde dehydrogenase activity. showed activity. In particular, Leuconostoc mesenteroides KCTC 3505 (205.5 nmol NADH/min/mg protein), a standard strain of the same species, and PC1 (171.8 nmol NADH/min/mg protein), a positive control strain isolated from a commercially available hangover relief product. ) and PC2 (504.5 nmol NADH/min/mg protein), it was confirmed that the VITA-PB2 strain of the present invention exhibits about 2 to 5 times higher acetaldehyde decomposition enzyme activity at 1113 nmol NADH/min/mg protein.

< Example 4. probiotics Characteristic measurements>

4.1 Hemolysis Safety

The hemolytic stability of Leuconostoc mesenteroides VITA-PB2, which was confirmed to have a very high alcohol decomposition ability above, was confirmed. As a positive control, a hemolytic test was performed using Bacillus cereus. The aspects of strains cultured on blood agar containing 7% Sheep Blood Defibrinated (MB-S1876) are largely divided into three categories: α-hemolysis hemolytic activity, β-hemolysis hemolytic activity, and γ-hemolysis hemolytic activity. In the case of strains with α-hemolysis hemolytic ability, the colonies formed by partially hemolyzing red blood cells turn green, but there is no change in the medium. In the case of strains with the hemolytic ability of β-hemolysis, a clear zone is created around the colony due to the complete hemolytic ability that completely destroys red blood cells, but strains with the hemolytic ability of γ-hemolysis cannot decompose red blood cells and colonies form. is formed, but there is no change in the medium.

The bacteria cultured according to the method of Example 2.1 above were smeared on a blood agar medium containing 7% sheep blood, cultured at 37°C for 24 hours, and the hemolytic property of each strain was confirmed through the final culture pattern. is shown in Figure 4. As shown in Figure 4, the VITA-PB2 strain according to the present invention was confirmed to be γ-hemolytic when compared to Bacillus cereus, a positive control.

4.2 Confirmation of cytotoxicity

MTT assay was performed to confirm the toxicity of VITA-PB2 of the present invention in mouse macrophages.

The MTT (2-2(4,5-dimethyl-thiazol)-2,5-diphenyltetrazolium bromide) assay measures the degree to which MTT is reduced and precipitated into formazan crystals by the enzymatic action of viable cells by absorbance, and then added from this. This is an experimental method to determine the extent to which cells are killed or proliferation is inhibited by lactic acid bacteria and culture media. Mouse macrophages were cultured in a 96 well plate at a cell density of 1×10 ⁵ cells/well for 24 hours in medium supplemented with 10% FBS and 1% antibiotic-antimycotic, then treated with VITA-PB2 diluted by concentration. did. Afterwards, cells were treated with MTT solution, and untreated cells were used as a control group and are shown in Figure 5. As shown in Figure 5, it was confirmed that no cytotoxicity was observed when treated with VITA-PB2.

4.3 bile salts Deconjugation Safety (Bile-salt coagulation)

In the case of bile salts, they help decompose fatty acids by emulsifying fat and promoting the action of lipase. Bile salt hydrolase present in probiotics protects probiotics from bile salts and increases their colonization in the intestines, but it also deconjugates bile salts, eliminating the emulsification function of bile salts and making it difficult to decompose fatty acids.

Accordingly, the safety of damjeum salt deconjugation of the selected VITA-PB2 strain was confirmed. The strain was smeared on MRS agar medium containing or not containing 0.5% taurodeoxycholic acid (TDCA; TRC INC,), cultured anaerobically at 37°C for 24 to 48 hours, and the colony pattern of the grown strain was confirmed. The results are shown in Figure 6. As shown in Figure 6, when the colony pattern of the strain grown in MRS medium containing 0.5% TDCA was compared with the strain in control MRS medium without 0.5% TDCA, there was no significant difference in the growth pattern of the strain, and the colony growth pattern was not significantly different. No small particles were formed around the area or the boundaries of the colonies were blurred. Therefore, in the case of the VITA-PB2 strain, it was confirmed to be negative in the production of deconjugated bile salts.

< Example 5. Identification of final selected strains>

Through the above experiments, strain VITA-PB2, which had excellent alcohol and acetaldehyde decomposition ability, was finally selected. As a result of 16S rRNA gene identification of VITA-PB2 strain, Leuconostoc mesenteroides mesenteroides ) and is shown in Figure 1. The above strain is effective as of November 7, 2022 It was deposited at the Korea Research Institute of Bioscience and Biotechnology Biological Resources Center. (Microorganism accession number: KCTC19046P)

Through the above experiments, a novel lactic acid bacterium, Leuconostoc mesenteroides VITA-PB2 ( Leuconostoc mesenteroides VITA), has high alcohol tolerance, alcohol and acetaldehyde decomposition ability, hemolytic safety, no cytotoxicity, and bile salt deconjugation safety. -PB2, KCTC19046P) was finally discovered, and it is expected that the novel lactic acid bacterium Leuconostoc mesenteroides VITA-PB2 ( Leuconostoc mesenteroides VITA-PB2, KCTC19046P) of the present invention can be used in pharmaceutical compositions for hangover relief, health functional foods, etc. do.

< Example 1. Pharmaceutical preparations>

400 g of the novel lactic acid bacterium Leuconostoc mesenteroides VITA-PB2 (KCTC19046P) of the present invention or its culture concentrate powder was mixed with 175.9 g of lactose, 180 g of potato starch, and 32 g of colloidal silicic acid. A 10% gelatin solution was added to this mixture, then pulverized and passed through a 14 mesh sieve. This was dried, and 160 g of potato starch, 50 g of activator, and 5 g of magnesium stearate were added thereto, and the resulting mixture was made into tablets.

< Example 2. Manufacturing of food>

Example 2-1. Manufacturing of health functional foods

2 g of the novel lactic acid bacterium Leuconostoc mesenteroides VITA-PB2 (KCTC19046P) of the present invention or its culture concentrate powder, appropriate amount of vitamin mixture, 70 μg of vitamin A acetate, 1.0 mg of vitamin E, 0.13 mg of vitamin B1 , Vitamin B2 0.15㎎, Vitamin B6 0.5㎎, Vitamin B12 0.2㎍, Vitamin C 10㎎, Biotin 10㎍, Nicotinamide 1.7㎎, Folic Acid 50㎍, Calcium Pantothenate 0.5㎎, mineral mixture, ferrous sulfate 1.75㎎, 0.82 mg of zinc oxide, 25.3 mg of magnesium carbonate, 15 mg of potassium phosphate monobasic, 55 mg of calcium phosphate dibasic, 90 mg of potassium citrate, 100 mg of calcium carbonate, and 24.8 mg of magnesium chloride were mixed to prepare granules.

Sequence list electronic file attached

Claims (6)

A novel lactic acid bacterium Leuconostoc mesenteroides VITA-PB2 ( Leuconostoc mesenteroides VITA-PB2, KCTC19046P). A pharmaceutical composition for relieving a hangover, comprising the novel lactic acid bacterium Leuconostoc mesenteroides VITA-PB2 (KCTC19046P) of claim 1 or a culture solution thereof. According to paragraph 2,
A pharmaceutical composition for relieving a hangover, characterized in that the pharmaceutical composition has the ability to decompose acetaldehyde. According to paragraph 2,
The pharmaceutical composition is a pharmaceutical composition for relieving a hangover, characterized in that it is formulated with one selected from the group consisting of powders, granules, tablets, capsules, suspensions, emulsions, syrups and solutions. A hangover relief food containing the novel lactic acid bacterium Leuconostoc mesenteroides VITA-PB2 (KCTC19046P) of claim 1 or its culture solution. According to clause 5,
The food is a food for relieving a hangover, characterized in that it is one of fermented milk, fermented red ginseng food, fermented soybean food, cheese, soy milk, tofu, beverage, powdered milk, baby food, raw food, beverage, sun food, or health supplement.